● Recruiting

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Condition: Hemophilia A · Sponsor: Hoffmann-La Roche

PhasePhase 1/Phase 2

Planned participants5

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.

This description comes directly from the study's public registry record.

Talk to the study team

Reference Study ID Number: XO46084 https://forpatients.roche.com/ No email attachments. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Always discuss trial participation with your own doctor first.

Locations (2)

Center for Inherited Blood Disorders	Orange, California, United States	Recruiting
Kaiser Permanente	Vallejo, California, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07226206